RxDoctor Payments Data

Rominder Kaur, MD

Internal Medicine · Highland Village, TXNPI 1902899396

Payments from drug & device makers

$2,965in general payments, 2019–2025

Across 127 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$869
  • Novo Nordisk$296
  • AstraZeneca$238
  • Amgen$226
  • GSK$150
  • Astellas Pharma US Inc$140
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,965100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,965 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$83,520
Medicare patients
128
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate28$18,067
JardianceEmpagliflozin26$17,337
MounjaroTirzepatide15$16,281
OzempicSemaglutide17$15,839
LinzessLinaclotide16$9,399
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,405
Wixela InhubFluticasone Propion/Salmeterol13$2,732
Advair DiskusFluticasone Propion/Salmeterol12$2,430
SynthroidLevothyroxine Sodium41$2,393
Levothyroxine Sodium341$2,093
Rosuvastatin Calcium215$1,765
Metoprolol Succinate115$1,691
Omeprazole102$1,672
Atorvastatin Calcium217$1,600
Amlodipine Besylate309$1,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$869$17,33726 claims
Lilly USA, LLCMounjaro$61$16,28115 claims
Novo NordiskOzempic$296$15,83917 claims
AbbVieLinzess, Synthroid$47$11,79157 claims
PfizerPaxlovid$110$1,35915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Highland Village

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →